Table 3.
Relationship between NCAPH immunoreactivity and clinicopathological parameters in ER-positive breast cancer patients.
| NCAPH Status | p-Value | |||
|---|---|---|---|---|
| Positive IR (n = 63) |
Negative IR (n = 45) |
|||
| Age | ≤50 years old | 32 | 21 | 0.344 |
| >50 years old | 31 | 24 | ||
| Stage | I | 21 | 21 | 0.161 |
| II, III | 42 | 24 | ||
| Invasive tumor size | ≤20 mm | 35 | 25 | 1.000 |
| >20 mm | 28 | 20 | ||
| Lymph node status | Positive | 28 | 15 | 0.245 |
| Negative | 35 | 30 | ||
| Nuclear grade | 1 | 31 | 29 | 0.116 |
| 2, 3 | 32 | 16 | ||
| PgR status | Positive | 51 | 41 | 0.143 |
| Negative | 12 | 4 | ||
| HER2 status | Positive | 9 | 5 | 0.628 |
| Negative | 54 | 40 | ||
| OCT1 status | Positive IR | 42 | 6 | <0.001 |
| Negative IR | 21 | 39 | ||
Note: Significant p-value is expressed in bold. Abbreviations: ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; IR, immunoreactivity; PgR, progesterone receptor.